$MRNA shares bounced as Q3 revenue grew 29% to $1.3B. $XBI Net income reached $162M, aided by a 27% drop in research spending. Management raised full-year grow

$MRNA shares bounced as Q3 revenue grew 29% to $1.3B. $XBI Net income reached $162M, aided by a 27% drop in research spending. Management raised full-year growth guidance to between 15%-25% while cutting capital spending to $200M. Pipeline execution remains critical, with filings ahead for intisme…